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Polyclonal antisera against prostaglandins (PGs) are widely used for the assessment of the biological role 
of these mediators, but even the most specific contain antibodies against the major metabolites and degrada- 
tion products of the haptens employed. To overcome this inherent problem we produced monoclonal anti- 
bodies (mAs) against PGE2, PGF2, and 6-keto-PGF,, using the somatic cell hybridization technique. The 
mAs against 6-keto-PGF,, and PGFza proved to be highly specific, but allowed only for moderate detection 
limits (l-2 ng) in conventional fluid phase radioimmunoassays (RIAs). One of the mAs against PGE? per- 
mitted a lOO-fold improvement in the detection limit while being aimost devoid of cross-reactivity with me- 
tabolites and other structurally related PGs. These results show that highly specific mAs against PGs can 
be produced to improve the available RIA technique for PC quanti~cation. 
Ceil hybridization Prostagiandin EJ Prostaglandin Fzn 6-Z&to-PGFt, Rad~oi~lm~no~ssay 
1. INTRODUCTION 
Prostaglandin (PG) Ez, a major eicosanoid in 
man, is involved in a variety of physiological and 
pathological events [I]_ Multiple attempts have 
hence been made to raise antibodies of sufficient 
specificity to qualify for direct radioimmunoassay 
(RIA) of E-series PGs in biological samples 
[2-131. However, the production of such an- 
tibodies (Abs) proved difficult, probably due to 
the chemical and metabolic instability of the 
hapten. Dehydration at the 11-hydroxy position 
resulting in the formation of A- and B-series PGs 
may occur during the coupling reaction of the 
hapten to the immunogen as well as by plasma 
isomerase enzymes [14,15]. The resulting 
polyclonal antibodies hence often recognize PGEz, 
PGAz and PGBz as well as other structurally 
related PGs to an extent which excludes them from 
being used in the specific determination of PGEz. 
Some research groups, either by serendipity and 
specific skills [ 13,15,16] or due to a specific 
strategy such as using stable PGEz analogues as 
haptens [17], were able to overcome this problem 
partially. An alternative approach would be the 
production of monoclonal antibodies (mAs) as 
suggested [18] using the cell hybridization tech- 
nique [ 191. A suitable mA against PGEz should be 
devoid of major cross-reactions against PGA2, 
PGB2, other metabolites of PGE2 and related PGs. 
Moreover, such mAs can be produced in almost 
unlimited quantities of a uniform standard in 
vitro, once a satisfying hybridoma cell line has 
been produced. 
Previously we reported that the production of 
such cell lines is possible 1201. Now we describe an 
mA against PGE2 which compares favourably with 
polyclonal Abs in that it allows for the develop- 
ment of highly sensitive and specific RIAs. 
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2. MATERIALS AND METHODS 
2.1. Materials 
All prostaglandins were generous gifts from Up- 
john Co. (Kalamazoo, USA) or bought from 
Sigma Chemie (Taufkirchen, FRG). [5,6,8,11,12, 
14,15(n)-3H]PGEz (spec. act. 160 Ci/mmol) was 
purchased from New England Nuclear (Dreieich, 
FRG). [5,6,8,9,11,12,14,15(n)-3H]PGF~ (spec. 
act. 180 Ci/mmol), 6-keto[5,8,9,11,12,14,15(n)- 
3H]PGF1, (spec. act. 150 Ci/mmol) and [5,6,8,11, 
12,14,15(n)-3H]PGA2 (spec. act. 160 Ci/mmol) 
were bought from Amersham Buchler (Braun- 
schweig, FRG). [3H]PGB2 was prepared according 
to the method of Zusman [21] from [3H]PGEz. 
2.2. Methods 
2.2.1. Coupling 
The haptens (PGEz, 6-keto-PGFr,, PGFh) were 
covalently bound to bovine serum albumin (BSA) 
with l-ethyl-3-(3-methylaminopropyl)carbodi- 
imide-HCl (both from Sigma, Taufkirchen) as 
coupling reagent according to the method of Dray 
et al. [18]. 
2.2.2. Immunization 
About 8-week-old Balb/c mice (Q Q ) were first 
immunized with 20rg PG-BSA conjugate, 
emulsified with an equal volume of complete 
Freund’s adjuvant (Difco, Detroit) and injected 
S.C. in the neck region and i.p. The second injec- 
tion was given 3 days later in the same way, with 
incomplete Freund’s adjuvant. Booster injections 
were given every 7 days i.p. with 2Opg antigen. 
Specific [3H]PG binding of plasma was monitored 
between the booster injections. 
2.2.3. Fusion and selection of clones 
Three days after the last booster injection (4 
weeks after the first) mice with high-titre plasma 
were bled and their spleens removed. Fusion of the 
spleen cells with an aminopterin-sensitive myeloma 
cell line (X63 Ag8.653, gift from G. Kohler, MPI, 
Freiburg) was performed using a solution of 42% 
polyethylene glycol (PEG) 4000 (Merck, Darm- 
stadt) with 15% dimethyl sulfoxide (DMSO) by the 
method of Kohler and Milstein [19]. Resulting cell 
suspensions were fed with the selective medium 
containing hypoxanthine, aminopterin and 
thymidine. The hybridoma culture supernatants 
were tested for antibody production by determin- 
ing specific [3H]PG binding of the corresponding 
hapten. Selected hybridoma cells were cloned twice 
by limiting dilution on feeder layers of mouse 
peritoneal macrophages. 
2.2.4. Production of mAs 
Clones were expanded in Dulbecco’s modified 
Eagle medium (DMEM) without phenol red 
(Biochrom, Berlin), completed with 1 mM sodium 
pyruvate, 2 mM L-glutamine, 0.05 mM 2-mercap- 
toethanol (Sigma, Taufkirchen) and 20% foetal 
calf serum (FCS) (all Gibco, Karlsruhe). The 
culture medium was collected every 3-4 days, con- 
centrated and lyophilized. 
2.2.5. Characterization 
Sensitivity of RIAs and cross-reactions were 
determined by binding inhibition assays [22]. The 
percentage of relative cross-reaction was calculated 
as 
ng homologous inhibitor at 50% binding of radiolabel 
x 100 
ng cross-reactive inhibitor at 50% binding of radiolabel 
The sensitivity of RIAs was calculated as the 
quantity of homologous inhibitor at 90% binding 
of the radiolabel (10% inhibition of binding as 
compared to buffer controls). The subclasses of 
the monoclonal antibodies were identified by an 
enzyme-linked immunosorbent assay (ELISA), us- 
ing class-specific rabbit-anti-mouse IgG and goat- 
anti-mouse IgG (2a,x,A) (Nordic Immunol. Lab., 
Tilburg, The Netherlands). Rabbit-anti-mouse IgG 
peroxidase and goat-anti-mouse IgG peroxidase 
were purchased from Dakopatts (Copenhagen). 
3. RESULTS 
The results are given in table 1 and fig.1. The 
mAs against PGFti and 6-keto-PGFi, showed a 
high degree of specificity displaying only about 1% 
cross-reactivity with the structurally related PGE2, 
PGEr and PGFi, (table 1). These mAs, however, 
allowed only for the measurement of fairly high 
concentrations of 6-keto-PGFi, or PGFh (> 1 ng) 
when used in the conventional RIA in solution 
employed by us routinely [23]. In contrast, our 
first mA against PGEz (E2Ri) allowed for the 
detection of much smaller amounts of PGE2 
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Table 1 
Characteristics of monoclonal antibodies against E- and F-type prostaglandins 
Prostaglandins 
PGEz 
PGE, 
PGAz 
PGBz 
PGDr 
PGF2, 
PGFI, 
TXB2 
TXB, 
15-Keto-PGE2 
15-Keto-13,14-dihydro-PGE2 
11-Deoxy-15-keto-13,14-dihydro- 
11,16-cycle-PGEz 
15-Keto-13,14-dihydro-PGFzcu 
15-Keto-PGFb 
6-Keto-PGF,, 
6,15-Diketo-PGFr, 
6,15-Diketo-13,14-dihydro-PGFr, 
Arachidonic acid 
Cross reaction (vo) 
mA-PGE2 (EzR2) mA-PGE2 (E2Rr) mA-6k-PGFr, 
100 100 1.83 
5.54 18.5 1.37 
(12) 
0.32 n.t. n.t. 
(5) 
0.79 n.t. n.t. 
0.12 <1.3 <l 
0.17 21.6 0.67 
0.33 n.t. 1.83 
<0.05 < 1.3 <l 
n.t. n.t. <l 
1.32 n.t. n.t. 
(2) 
0.97 n.t. n.t. 
< 0.05 n.t. n.t. 
< 0.05 n.t. n.t. 
<0.05 n.t. n.t. 
0.07 100 100 
0.07 n.t. <1 
0.06 n.t. <l 
<0.05 n.t. n.t. 
mA-PGFh 
1.32 
2.42 
n.t. 
n.t. 
<l 
100 
2.05 
<l 
<1 
n.t. 
n.t. 
n.t. 
<l 
<1 
n.t. 
n.t. 
n.t. 
n.t. 
Sensitivity (ng) 0.03 0.22 1.1 2.0 
(0.01) 
Immunoglobulin subclass JgGl, IgGl, fgG1, IgGl, 
X- 1 .-chains x- 1 .-chains a-l.-chains x-1 .-chains 
Values in parentheses give characteristics of a specific antiserum against PGEz (32-7) used for comparison [11,22]. n.t., 
not tested 
(> 200 pg) but its cross-reaction with 6-keto-PGFt, 
(loo%), PGEl and PGFb was considerable. The 
second mA against PGE2 (E2R2) proved to be very 
specific, displaying some cross-reactivity only with 
PGEi (-5%), and 15keto-PGE2 (1010), but not 
with, e.g., 6-keto-PGFr, or a great variety of other 
PGs. It compared very well in that respect with a 
widely used antiserum (table 1). In addition, this 
mA if employed in the conventional fluid phase 
RIA allowed for the detection of small amounts of 
PGE2 (30 pg). In further experiments (fig. 1) it was 
shown that this mA was devoid of the ability to 
bind [3H]PGAz and [3H]PGB2, which is usually 
displayed by antisera against PGE2. As shown in 
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fig. 1, even at high concentrations the mA-PGE2 
does not bind PGA2 or PGB2 while the antiserum 
does (for details see [ 11,241). The immunoglobulin 
subclass of all mAs was defined as IgGl with K- 
light chains. 
4. DISCUSSION 
Our results show that it is possible to raise 
hybridoma clones which produce monoclonal an- 
tibodies against PGs in vitro. Some of these mAs 
can be used in conventional RIAs, allowing for the 
direct and sensitive detection of biologically rele- 
vant PGs. For example, our mA-PGE2 (E2R2) is 
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Fig.1. (a,b) Binding of [3H]PGE2 (o), 13H]PGAz (c) 
and [3H]PGB2 (A) at equal specific activity by dilutions 
of (a) specific poiyclonal antiserum (32-7), (b) mA-PGE2 
(E2R2) cuiture supernatant. 
now routinely used in a standard RIA assessing the 
prostaglandin release from macrophages yielding 
almost identical results as compared to a well 
defined specific antiserum against PGE2 ([11,24] 
and table 1). The mA-&keto-PGFi, and mA- 
PGFh are not of comparable quality in conven- 
tional fluid phase assays due to relatively high 
detection limits. They have, however, proven 
useful when employed in an immunosorbent assay 
on plastic surface to be reported elsewhere. 
The mA concentration in hybridoma super- 
natants is high enough for the direct use of these 
supernatants in the assay procedure. For example, 
the dilutions given in the figure are direct dilutions 
from pooled hybridoma supernatants harvested 
after approx. 3 days (cell count at that time -5 x 
106/ml). In other words, it is not necessary to in- 
itiate the production of mAs in the peritoneal cavi- 
ty of Balb/c mice for sufficient mA concentra- 
tions. Furthermore, our data prove that it is possi- 
ble to circumvent problems inherent to conven- 
tionally produced polyclonal antisera. The mA- 
PGFti, mA-6-keto-PGFi, and the mA-PGEz 
(EzRt) exert a high degree of specificity, i.e., these 
antibodies can discriminate well between minor 
structural differences in the side chains of PGs and 
in the ring structure. The mA-PGE2 (EzRz), for ex- 
ample, is able to detect minor changes in the side- 
chain configuration as present in PGEi or in 
15-keto-PGEz although with some cross-reactivity, 
but there is no detectable cross-reactivity with 
PGFh, PGA2 or PGB2 which differ in the sub- 
stituent configuration of the cyclopentane ring. 
The small (5%) cross-reactivity with PGEi is less 
than with even the best anti-PGEz antisera. Fur- 
thermore, it is of Iittle relevance under most ex- 
perimental conditions due to the low production of 
PGEi by most mammalian cells [25]. Moreover, 
the inherent problem of PGEz-antisera, namely, 
that they contain antibodies against PGAz and 
PGB2 [l l] is avoided by selecting a clone, which 
can only produce one species of antibodies. By this 
procedure one can obtain antibodies which are 
much more specific than those produced by the 
elegant method of Fitzpatrick and Bundy [17] who 
employed the metabolically stable PGEz analogue, 
9-deoxy-9-methylene-PGFb. 
Finaily, it should be mentioned that we are now 
in a position to produce specific antibodies of a 
uniform standard in almost unlimited quantities. 
By feeding our hybridomas with labelled amino 
acids we can produce labelled antibodies which 
should prove particularly valuable in assays based 
on labelled antibodies instead of labelled antigens 
[26]. This option together with the relative ease of 
purifying monoclonal antibodies from culture 
supernatants is even likely to initiate the displace- 
ment of conventional RIAs by assays based on 
purified antibodies labelled with isotopes, 
fluorescence markers or enzymes. 
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